Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
Abstract The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is...
Main Authors: | Yi Huang, Hua Jiang, Yun Chen, Xiaqiong Wang, Yanqing Yang, Jinhui Tao, Xianming Deng, Gaolin Liang, Huafeng Zhang, Wei Jiang, Rongbin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-04-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201708689 |
Similar Items
-
Tranilast Directly Targets NLRP3 to Protect Melanocytes From Keratinocyte-Derived IL-1β Under Oxidative Stress
by: Tongtian Zhuang, et al.
Published: (2020-07-01) -
The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
by: Yang Gyun Kim, et al.
Published: (2019-11-01) -
Pharmacological Inhibitors of the NLRP3 Inflammasome
by: Ayesha Zahid, et al.
Published: (2019-10-01) -
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast
by: Noakes R
Published: (2018-07-01) -
Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
by: Sonia Missiroli, et al.
Published: (2021-05-01)